Feeling Sick After Gluten? A Deep Dive into Celiac Disease Pathogenesis

Celiac disease (CD) is a genetic, lifelong autoimmune disorder in which the immune system mistakenly attacks the small intestinal lining when a person consumes gluten proteins found in wheat, barley, and rye. This leads to villous atrophy and malabsorption. It affects about 1% of the global population, with a slightly higher prevalence in females. Symptoms vary widely: classic presentations include diarrhea, weight loss, bloating, and anemia, while non-classic forms may involve skin issues, osteoporosis, neurological symptoms, or even asymptomatic (silent) disease. The gold-standard diagnosis remains small intestinal biopsy, showing villous atrophy, crypt hyperplasia, and lymphocytic infiltration. Although a strict, lifelong gluten-free diet (GFD) is currently the only standard treatment, recent scientific advances are opening the door to a "post-GFD era."

Pathogenesis

The majority of celiac disease cases are driven by genetics: approximately 95% of patients carry the HLA-DQ2 or HLA-DQ8 alleles, which encode molecules capable of efficiently presenting deamidated gluten peptides. Gluten peptides cross the intestinal epithelium into the lamina propria, where they are deamidated by tissue transglutaminase 2 (TG2), increasing their binding affinity to HLA-DQ2/8. Antigen-presenting cells then activate CD4+ T cells, which release IFN-γ, TNF-α, and IL-15, causing epithelial damage and villous atrophy. Autoantibodies targeting TG2 and deamidated gluten peptides further amplify the inflammatory response. Innate immunity plays a role as well, with epithelial cells releasing IL-15, which upregulates NKG2D on CD8+ T cells and triggers cytotoxic damage. Genome-wide association studies have also identified non-HLA susceptibility loci, including IL2/IL21, IL18RAP, SH2B3, PTPN2, UBE2L3, and TNFAIP3, which collectively implicate T-cell signaling, cytokine pathways, and NF-κB regulation in disease susceptibility.

Figure 1. Pathophysiology of celiac disease and current investigational therapeutic strategies

Genetics alone do not determine disease — environmental and microbial factors also play critical roles.

Gut dysbiosis: Studies show increased pathogenic bacteria (e.g., Escherichia coli, Staphylococcus) and reduced beneficial species (e.g., Bifidobacterium) in celiac patients. Certain protease-secreting bacteria degrade gluten into more immunogenic peptides, while bacterial accessory proteins may act as adjuvants, heightening immune sensitivity to gluten.

Viral infection and loss of immune tolerance: Infections such as reovirus or human herpesviruses may disrupt intestinal immune homeostasis. Viral-triggered proinflammatory signals (e.g., IFN-α) can mislead the immune system into recognizing otherwise tolerated gluten antigens as threats, breaking tolerance and triggering disease.

Figure 2. Potential roles of microbiota and environmental triggers in celiac disease pathogenesis

Key Research Targets and Drug Development Progress

The following table highlights major research targets in celiac disease, focusing on different steps in the pathogenic pathway and offering potential therapeutic strategies.

Advances in Diagnostic Techniques

1. Serology as the first-line standard: tTG-IgA (tissue transglutaminase IgA antibody) remains the preferred screening test; DGP (deamidated gliadin peptide antibodies) provide valuable supplementary information in IgA-deficient individuals and young children.
2. Biopsy-free diagnosis in children: The latest ESPGHAN guidelines state that if tTG-IgA levels are >10× upper limit of normal and EMA (endomysial antibodies) are positive, combined with HLA genotyping, intestinal biopsy may be omitted.
3. AI-assisted capsule endoscopy: Deep learning algorithms automatically detect villous atrophy in capsule endoscopy images, addressing the issue of "patchy" sampling errors in conventional biopsy.

abinScience Related Products

The following products from abinScience target core celiac disease research pathways, including the TG2 autoantigen, HLA-DQ antigen presentation, IL-15-mediated innate immunity, gliadin detection, and GWAS-implicated susceptibility loci. Click the catalog numbers to go directly to the product pages.

Antibody

Protein

References:
1. Lebwohl B, Sanders DS, Green PHR. Coeliac disease. Lancet. 2018;391(10115):70-81. doi: 10.1016/S0140-6736(17)31796-8
2. Schuppan D, Mäki M, Gliadin Z, et al. A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease. N Engl J Med. 2021;385(1):35-45. doi: 10.1056/NEJMoa2032441
3. Kelly CP, Murray JA, Leffler DA, et al. TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study. Gastroenterology. 2021;161(1):66-80. doi: 10.1053/j.gastro.2021.03.014
4. Leffler DA, Kelly CP, Green PH, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015;148(7):1311-1319. doi: 10.1053/j.gastro.2015.02.008
5. Trynka G, Hunt KA, Bockett NA, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet. 2011;43(12):1193-1201. doi: 10.1038/ng.998
6. Ferranti P, Ferrara C, Mancuso M, et al. New therapies in celiac disease. Curr Opin Gastroenterol. 2025;41(3):124-131. doi: 10.1097/MOG.0000000000001080